Established in 1946, the Social Medical Corporation Boai Society (Kagoshima City) is dedicated to women's medical care and cancer treatment with a focus on breast cancer treatment, from prevention and screening to treatment and palliative care, and has earned a reputation throughout Japan as a specialist breast cancer hospital. Based on the expertise and quality of care cultivated for women's medical treatment, we promote a full range of treatment for women with a broader range of response capabilities.
One of its features is the realisation of a complete medical system from prevention and health screening to diagnosis, treatment, post-operative support and therapy. By closely linking the various stages, all aspects of the medical condition can be longitudinally addressed.
The POH and Siemens Healthcare have joined forces as the only Siemens site in Asia to introduce advanced medical equipment and provide high-precision diagnosis and treatment through a global exchange of knowledge.
In August 2014, the hospital received accreditation as a Collaborative Base Hospital for Specific Regional Cancer Treatment (Breast Cancer) from the Japanese Ministry of Health, Labour and Welfare. Sagara Hospital is the only "Specific Regional Cancer Treatment Cooperative Base Hospital" in breast cancer in Japan. As a Cancer Genomic Medicine Cooperative Hospital promotes personalised cancer treatment based on genetic predisposition.
Advanced Medical Treatment
Medical technology and science are changing rapidly. 2008 saw the introduction of genetic clinics for hereditary breast cancer and ovarian cancer syndrome, and in April 2020, diagnosis, preventive treatment and screening for hereditary breast cancer was made available to many people in Japan with insurance coverage. Currently, pathologists, genetic disease-related doctors, physicians, nurses and laboratory technicians are among the many staff involved in providing highly specialised medical services.
Promotion of clinical trials and clinical research
We are also actively engaged in clinical research to develop new therapies and drugs. The Hospital's experts are engaged in clinical research at the Dana-Farber Cancer Institute and the Harvard School of Public Health in the United States, and have announced the results of studies on new treatment strategies for early-stage breast cancer. It has received widespread attention worldwide. In addition, we collaborate with national and international companies and clinical research groups specialising in cancer research to develop new cancer diagnostics and diagnostic imaging using genetic diagnostics to predict cancer recurrence and AI. Patient safety is our top priority, with ethics committees reviewing the validity and safety of studies and clinical research coordinators supporting patients.
Practising patient-centred care
The important thing for our healthcare professionals is to provide peace of mind for patients and their families in outpatient clinics and wards, and to deliver patient-centred care. Based on highly reliable evidence, we strive to provide better healthcare through a variety of options that suit the values and lifestyles of each patient.
Breast Centre
A high level of trust in medical care supported by the country's second to none number of surgical cases and extensive experience.
Examination: high-precision examinations by female technicians. Over 40 years of experience in the field of breast cancer treatment. In addition to 3D mammography, PET-MR, which has been introduced in only a few hospitals worldwide, is also available.
Surgery: Low-load surgery in collaboration with plastic surgery. 697 cases of breast cancer surgery in 2016, ranking No.1 in Japan.
Pre- and post-operative treatment: reliable treatment based on scientific evidence, personalised treatment according to the extent of the breast cancer.
